Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
CCR4 (C-C Motif Chemokine Receptor 4)
i
Other names:
CCR4, C-C Motif Chemokine Receptor 4, CC-CKR-4, CMKBR4, K5-5, Chemokine (C-C Motif) Receptor 4, C-C Chemokine Receptor Type 4, C-C CKR-4, ChemR13, CD194, CCR-4, CKR4, Chemokine (C-C) Receptor 4, CD194 Antigen, HGCN:14099
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1233
Associations
(10)
News
Trials
VERI cancer hierarchy
Reset Filters
CCR4 positive
Leukemia
CCR4 positive
Leukemia
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
CCR4 positive
Lymphoma
CCR4 positive
Lymphoma
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
CCR4 negative
Solid Tumor
CCR4 negative
Solid Tumor
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
mogamulizumab-kpkc
Sensitive: C2 – Inclusion Criteria
mogamulizumab-kpkc
Sensitive
:
C2
CCR4 overexpression
Head and Neck Cancer
CCR4 overexpression
Head and Neck Cancer
FLX475
Sensitive: C3 – Early Trials
FLX475
Sensitive
:
C3
FLX475
Sensitive: C3 – Early Trials
FLX475
Sensitive
:
C3
CCR4 overexpression
Head and Neck Cancer
CCR4 overexpression
Head and Neck Cancer
pembrolizumab + FLX475
Sensitive: C3 – Early Trials
pembrolizumab + FLX475
Sensitive
:
C3
pembrolizumab + FLX475
Sensitive: C3 – Early Trials
pembrolizumab + FLX475
Sensitive
:
C3
CCR4 overexpression
Nasopharyngeal Carcinoma
CCR4 overexpression
Nasopharyngeal Carcinoma
FLX475
Sensitive: C3 – Early Trials
FLX475
Sensitive
:
C3
FLX475
Sensitive: C3 – Early Trials
FLX475
Sensitive
:
C3
CCR4 overexpression
Nasopharyngeal Carcinoma
CCR4 overexpression
Nasopharyngeal Carcinoma
pembrolizumab + FLX475
Sensitive: C3 – Early Trials
pembrolizumab + FLX475
Sensitive
:
C3
pembrolizumab + FLX475
Sensitive: C3 – Early Trials
pembrolizumab + FLX475
Sensitive
:
C3
CCR4 overexpression
Lymphoma
CCR4 overexpression
Lymphoma
FLX475
Sensitive: C3 – Early Trials
FLX475
Sensitive
:
C3
FLX475
Sensitive: C3 – Early Trials
FLX475
Sensitive
:
C3
CCR4 negative
Esophageal Cancer
CCR4 negative
Esophageal Cancer
mogamulizumab-kpkc
Sensitive: C3 – Early Trials
mogamulizumab-kpkc
Sensitive
:
C3
mogamulizumab-kpkc
Sensitive: C3 – Early Trials
mogamulizumab-kpkc
Sensitive
:
C3
CCR4 negative
Lung Cancer
CCR4 negative
Lung Cancer
mogamulizumab-kpkc
Sensitive: C3 – Early Trials
mogamulizumab-kpkc
Sensitive
:
C3
mogamulizumab-kpkc
Sensitive: C3 – Early Trials
mogamulizumab-kpkc
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.